Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EBT (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of EBT data on record, last reported at -$15.1 million in Q4 2025.

  • For Q4 2025, EBT fell 3.71% year-over-year to -$15.1 million; the TTM value through Dec 2025 reached -$59.8 million, down 41.54%, while the annual FY2025 figure was -$59.8 million, 41.54% down from the prior year.
  • EBT reached -$15.1 million in Q4 2025 per CTNM's latest filing, down from -$13.0 million in the prior quarter.
  • Across five years, EBT topped out at $42.3 million in Q2 2023 and bottomed at -$15.9 million in Q2 2025.
  • Average EBT over 3 years is -$6.6 million, with a median of -$9.6 million recorded in 2024.
  • Peak YoY movement for EBT: crashed 121.3% in 2024, then fell 3.71% in 2025.
  • A 3-year view of EBT shows it stood at -$7.9 million in 2023, then tumbled by 83.51% to -$14.6 million in 2024, then fell by 3.71% to -$15.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$15.1 million in Q4 2025, -$13.0 million in Q3 2025, and -$15.9 million in Q2 2025.